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ABSTRACT
Background and Aims: Platelet-derived growth factor receptor alpha (PDGFRα) 
is suggested as a prognosis marker for hepatocellular carcinoma (HCC). Since PDGFRα 
is also known as a marker for activated hepatic stellate cells (HSCs), this study aimed 
to investigate whether PDGFRα expression in HCC was dependent on the background 
liver fibrous condition.
Results: Strong PDGFRα expression in the tumor lesions was associated with 
decreased survival after curative HCC resection. Expression of PDGFRα in the tumor 
correlated with increased collagen α1(I), lecithin retinol acyltransferase, and smooth 
muscle α-actin suggesting increased HSCs in tumor sites. The expression of PDGFRα 
in the tumor sites was associated neither with underlying liver fibrosis/cirrhosis nor 
with the expression of PDGFRα in adjacent non-tumor sites of the liver.
Materials and Methods: Patients with HCC who underwent liver resection as 
curative treatment were included in this study. Using liver samples of 95 patients, tissue 
microarray was constructed and immunohistochemical study of PDGFRα was conducted 
in both tumor and non-tumor sites. PDGFRα expression in tumor and matching non-
tumor sites was compared. Freshly frozen liver tissue specimens of 16 HCC patients 
were used for gene expression analysis of PDGFRα and fibrosis related genes.
Conclusions: Our results suggest that PDGFRα overexpression in HCC is a 
prognostic marker independent of adjacent non-tumor site liver fibrosis status.
INTRODUCTION
Chronic liver injury due to infectious, inflammatory 
or metabolic disorders often results in liver fibrosis 
and cirrhosis, which may predispose to hepatocellular 
carcinoma (HCC) [1, 2]. Although liver fibrosis and 
cirrhosis are well known risk factors for HCC, contribution 
of fibrous microenvironment to liver carcinogenesis has 
not been clearly elucidated. A molecular profiling study 
of HCC and adjacent non-tumor site reported that instead 
of the tumor itself, the gene signature of the adjacent non-
tumor site contained important molecular information 
on HCC recurrence and prognosis [3]. This supports the 
possible significant role of stromal microenvironment to 
HCC carcinogenesis or progression.
Platelet derived growth factors (PDGFs) are potent 
mitogen for hepatic stellate cells (HSCs) which comprises 
an important cellular component in liver fibrosis and 
cirrhosis [4, 5]. The PDGF ligand family, PDGF-A, B, 
C, and D transmit extracellular signals through tyrosine 
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kinase receptors which consist of two subunits, platelet-
derived growth factor receptor (PDGFR) α and PDGFRβ 
[6, 7]. Increased PDGFRα is noticeable in cirrhotic liver 
and its primary expression is reported to be in HSCs [8]. 
Stimulation of PDGFR and overexpression of PDGF 
ligands may induce HSC proliferation [9-12]. Interestingly, 
overexpression of PDGF-C in hepatocytes and stimulation 
of PDGFRα results in not only liver fibrosis but eventually 
development of HCC, suggesting the significant role of 
PDGFRα in liver fibrosis and HCC tumorigenesis [13]. 
However, cellular target of PDGF-C, on which PDGFRα 
should be abundant, is still not clear. In non-cancerous 
condition, expression of PDGFRα is noticed on non-
parenchymal liver cells, mainly HSCs. Therefore it can 
be hypothesized that overexpressed PDGF-C would 
stimulate PDGFRα on HSCs, which in turn may lead to the 
activation and proliferation of the cells. These activated 
HSCs might contribute PDGFRα over-expression in 
HCC tumor sites. However, link between activation, 
proliferation of HSCs and HCC formation is still not clear.
Cellular source of PDGFRα is also under dispute. 
Increase of PDGFRα expression has been reported 
in cancerous hepatocytes [14], while another study 
demonstrated that they were non-parenchymal cells in 
tumor sites where PDGFRα were expressed [15]. In 
addition, although HCC is often preceded by liver fibrosis 
where increased PDGFRα expression is frequently 
detected, association of PDGFRα up-regulation in HCC 
and the condition of adjacent non-tumor site is to be more 
thoroughly investigated. If PDGFRα expression were to 
be associated with the status of underlying liver disease, 
it could have been suggested that characteristics of HCC 
were to be dependent on the background liver condition.
This study aimed to investigate whether PDGFRα 
expression in HCC is associated with the status of the 
underlying liver disease by assessing PDGFRα expression 
on tumor and matching non-tumor sites.
RESULTS
Patient characteristics
Demographic findings of patients that were 
included in immunohistochemistry (IHC) analysis of 
PDGFRα are described in Table 1. Patients were 29-75 
years in age (range, 53.2 ± 10.0), and mean follow-up 
time after surgery was 50.0 ± 39.3 months (range, 0-108). 
The etiology of underlying liver disease was HBV in 
73 (76.8%), HCV in 6 (6.3%), alcohol in 3 (3.2%) and 
others in 13 (13.7%) patients. Pathologic liver cirrhosis, 
determined from histologic evaluation of liver non-tumor 
site, was identified in 64 (67.4%) patients.
Clinicopathologic characteristics of the patients 
were compared according to PDGFRα expression patterns 
(Table 2). Patients with strong PDGFRα expression on 
HCC showed similar gender ratio, higher proportion of 
patients with AFP >200 ng/mL, and lower portion of 
patients with liver cirrhosis compared with patients with 
either no or moderate PDGRα stain.
Expression of PDGFRα in tumor and reciprocal 
non-tumor sites: tissue microarray study
PDGFRα expression was evaluated by a single 
pathologist, blinded to the patients’ clinical information. 
The assessment was done in both tumor and matching 
non-tumor site of each patient (Table 3). There was a 
significant difference in PDGFRα expression of tumor and 
non-tumor sites and strong expression of PDGFRα was 
not seen in non- tumor sites.
PDGFRα expression is high in embryonic liver 
and then declines to minimal levels in adult hepatocytes 
[14]. On the other hands, PDGFRα expression is known 
to be immensely increased in cirrhotic liver, mainly on 
αSMA positive non-parenchymal cells [15]. We evaluated 
whether PDGFRα expression in tumor sites were 
associated with underlying liver cirrhosis or non-tumor 
site PDGFRα expression (Table 4). The cases with weak 
intensity of PDGFRα stain were classified as negative 
in this analysis. Among 95 patients, 62 patients (65.3%) 
showed positive for PDGFRα on tumor sites. PDGFRα 
positivity on tumor sites was not associated with existence 
of pathologically detected liver cirrhosis on matching non-
tumor site. In addition, expression of PDGFRα on tumor 
sites had no relation with appearance of PDGFRα on 
reciprocal non-tumor sites (Table 4, Figure 1).
Association of PDGFRα expression and the 
clinical outcome after the curative HCC 
resection: tissue microarray study
Strong PDGFRα expression in tumor site was 
associated with decreased overall survival after curative 
HCC resection (p=0.001) (Figure 2).
Multivariate analysis test suggested that 
preoperatively elevated AFP above 200 ng/mL, existence 
of macrovascular invasion, having underlying liver 
diseases due to alcohol abuse were associated with poor 
survival in addition to strong PDGFRα positivity on tumor 
sites (Table 5).
PDGFRα positivity on tumor sites was not associated 
with HCC recurrence after curative resection (p=0.165) 
(Figure 3). Instead, multiple tumor mass, histologically high 
Edmonson grade and existence of macrovascular invasion 
were factors suggesting recurrence (Table 6).
Association of tumor site PDGFRα and fibrosis 
or cancer-associated fibroblast related genes
In order to evaluate whether PDGFRα expression 
on tumor site has association with genes for liver fibrosis 
or cancer-associated fibroblast, freshly frozen HCC 
Oncotarget39536www.impactjournals.com/oncotarget
specimens with matching non-tumor sites were used for 
mRNA quantification. Gene expression on normal liver, 
obtained from non-tumor sites of resected liver due to 
colon cancer metastasized to the liver, served as the 
control. Summary of the patients with PDGFRα mRNA 
expression in tumor and non-tumor site is described in 
Table 7.
Tumor site PDGFRα expression was correlated 
with increased collagen α1(I) (Col1α(I)) mRNA on 
tumor site (Table 8). Increased PDGFRα mRNA was also 
associated with increased lecithin retinol acyltransferase 
(Lrat), which is the marker for both activated and 
quiescent HSCs, and elevated smooth muscle α-actin 
(αSMA) expression, which is known as the marker for 
activated HSC and cancer-associated fibroblast. However, 
increased tumor site PDGFRα appeared to have no 
relation with non-tumor site PDGFRα, Col1α(I), and 
αSMA expression.
Association of underlying liver cirrhosis and 
gene expression pattern
Since PDGFRα, Col1α(I), Lrat, αSMA, and lysyl 
oxidase homolog 2 (LOXL2) are known as the marker 
for liver fibrosis, expression of these genes in non-tumor 
site was assessed in association with the existence of liver 
cirrhosis [16]. The analysis showed that except Lrat, which 
is also a marker for quiescent HSC, expression of Col1α(I), 
αSMA, and LOXL2 increased with accompanying liver 
cirrhosis in non-tumor site (Figure 4). On the other hands, 
expression of PDGFRα and αSMA in tumor site did not 
affected by underlying liver cirrhosis.
DISCUSSION
In accordance with other previous studies [14, 17, 18], 
our study also demonstrated that strong PDGFRα expression 
Table 1: Baseline characteristics of patients that underwent liver resection due to HCC
Variables n=95
Age, years, median (range) 54 (29-75)
Gender (M:F) 78:17
Etiology of Liver Disease
HBV 73 (76.8)
HCV 6 (6.3)
Alcohol 3 (3.2)
Others 13 (13.7)
Serum AFP, ng/mL (%)
≤200 58 (61.1)
>200 37 (38.9)
Tumor number (%)
Single 13 (13.7)
Multiple 82 (86.3)
Tumor size
≤5cm 65 (68.4)
>5cm 30 (31.6)
Existence of satellite nodule 10 (10.5)
Existence of microvascular invasion (%) 56 (55.4)
Existence of macrovascular invasion (%) 2 (2.1)
Edmonson Grade (%)
Grade 1, 2 46 (48.4)
Grade 3, 4 49 (51.6)
Existence of Pathologic Cirrhosis (%) 64 (67.4)
AFP, alpha-fetoprotein.
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in tumor sites was associated with poor survival outcome after 
HCC resection. However, the expression of PDGFRα did not 
necessarily associated with underlying liver fibrosis/cirrhosis 
or the expression of PDGFRα in adjacent non-tumor site 
of the liver. This result suggests that PDGFRα positivity in 
HCC does not necessarily associated with the process of liver 
fibrosis/cirrhosis in the background liver, but demonstrates the 
unique characteristics of HCC with poor prognosis.
Table 2: Association between baseline clinicopathologic characteristics and PDGFRα expression
Baseline characteristics No stain
(n=33)
Positive
(n=56)
Strong Positive
(n=6)
P
Age, years, median (range) 54 (33-71) 53 (29-75) 47 (34-63) 0.337
Gender (M:F) 29:4 46:10 3:3 0.092*
Etiology of Liver Disease 0.181
HBV 25 (75.8) 45 (80.4) 3 (50.0)
HCV 0 (0.0) 5 (8.9) 1 (16.7)
Alcohol 2 (6.1) 1 (1.8) 0 (0.0)
Others 6 (18.2) 5 (8.9) 2 (33.3)
Serum AFP, ng/mL (%) 0.044*
≤200 19 (57.6) 38 (67.9) 1 (16.7)
>200 15 (42.4) 18 (32.1) 5 (83.3)
Tumor number (%) 0.453
Single 6 (18.2) 7 (12.5) 0 (0.0)
Multiple 27 (81.8) 49 (87.5) 6 (100)
Tumor size 0.954
≤5cm 22 (66.7) 39 (69.6) 4 (66.7)
>5cm 11 (33.3) 17 (30.4) 2 (33.3)
Existence of satellite nodule 1 (3.0) 9 (16.1) 0 (0.0) 0.105
Existence of microvascular invasion (%) 3 (9.1) 11 (19.6) 2 (33.3) 0.235
Existence of LN metastasis (%) 1 (3.0) 1 (1.8) 0 (0.0) 0.863
Edmonson Grade (%) 0.284
Grade 1, 2 18 (54.5) 27 (48.2) 1 (16.7)
Grade 3, 4 15 (45.5) 29 (51.8) 5 (83.3)
Existence of Pathologic Cirrhosis (%) 20 (60.6) 42 (75.0) 2 (33.3) 0.068*
PDGFRα, platelet-derived growth factor α; AFP, alpha-fetoprotein; LN, lymph node, Percent is calculated within the group 
with the similar PDGFRα expressing patients; *P values that are <0.1 are considered to be significant.
Table 3: PDGFRα expression in paraffin sections
N=95 Tumor Site Non-Tumor Site P*
No stain
N (%)
Weak
N (%)
Moderate
N (%)
Strong
N (%)
No stain
N (%)
Weak
N (%)
Moderate
N (%)
Strong
N (%)
PDGFRα
19
(20.0)
14  
(14.7)
56
(58.9)
6
(6.3)
4
(1.2)
19
(20.0)
72
(75.8)
0
(0.0)
0.000*
PDGFRα, platelet-derived growth factor α; * P values that are <0.05 are considered to be significant when PDGFRα 
expressions are compared between tumor and non-tumor sites.
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Table 4: Association of PDGFRα in tumor site and liver cirrhosis
N=95 Tumor Site
PDGFRα (-) PDGFRα (+)
Non-tumor site
 PDGFRα (-) 6 (6.3%) 17 (17.9%) P=0.451
 PDGFRα (+) 27 (28.4%) 45 (47.4%)
Pathologic Liver Cirrhosis
 (-) 13 (13.7%) 18 (18.9%) P=0.610
 (+) 20 (21.1%) 44 (46.3%)
Number of the patients from the total patients (n=95) is expressed in percent.
PDGFRα, platelet-derived growth factor α.
Figure 1: A representative PDGFRα expression in non-tumor and tumor site of the same patient (immunohistochemistry, 
original magnificationX200). (A) Moderate PDGFRα expression in non-tumor site with no stain in tumor site, and (B) no stain in non-
tumor site with strong stain in tumor site.
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PDGFRα is reported to be up-regulated in the 
injured liver with fibrosis and beginning to be recognized 
as a potential mediator of HSC activation, leading to liver 
fibrosis [15, 19, 20]. PDGFRα mRNA is highly expressed 
in αSMA positive HSCs, an important cellular component 
in the liver that contributes to generation and progression 
of fibrosis [21]. A recent study also demonstrated that 
reducing PDGFRα signaling in heterozygous PDGFRα 
mice showed alleviation of liver fibrosis from CCl
4
 
injury [15]. On the other hands, excessive activation of 
PDGFRα signaling in PDGF-C transgenic mice resulted 
in liver cirrhosis by 9 months, and interestingly, these 
mice with cirrhosis develop liver cancer in the later stage, 
resembling human HCC with background liver cirrhosis 
[13]. In our study with human HCC samples, tumor site 
PDGFRα expression does not necessarily associated with 
the underlying liver cirrhosis and PDGFRα expression in 
the adjacent non-tumor sites.
Although PDGFRα expression in HCC may not 
be the consequence of liver fibrosis/cirrhosis, it should 
be emphasized that this suggestion does not preclude the 
possible communication between HSCs and tumor cells 
in the liver. HSC is one of the most important cellular 
components in the liver that contributes to generation and 
progression of fibrosis [22]. Upon liver injury, quiescent 
HSC transdifferentiate to extracellular matrix-producing 
myofibroblasts and overexpress various genes which is 
regarded as fibrosis related markers such as α-SMA and 
PDGFRα [23]. With the decades of the study, it has been 
widely recognized that HSCs seem to contribute in HCC 
progression [24, 25], when mechanism of this contribution 
is yet to be delineated.
In other solid tumors including pancreas cancer or 
intrahepatic cholangiocarcinoma, the abnormal activity 
of neoplastic epithelium is thought to stimulate stromal 
fibroblasts, resulting in the cancer associated desmoplastic 
response [26]. These abnormally stimulated fibroblasts 
are α-SMA positive cells and often designated as “cancer-
associated fibroblasts (CAF)”. In cases of HCC, α-SMA 
positive HSCs contribute generation of liver fibrosis 
and cirrhosis in non-neoplastic liver, and previous HCC 
molecular profiling study demonstrated that the gene 
signature of the non-tumor tissue, adjacent to the tumor 
site, contains critical molecular information on HCC 
prognosis [3]. Although this signature study supports the 
important role of fibrosis/cirrhosis as a microenvironment 
Figure 2: Survival after the curative resection of hepatocellular carcinoma (HCC) according to PDGFRα expression 
in tumor site. Patients with strong PDGFRα expression in tumor site has lowest survival rate (dashed line) when analyzed by log-rank 
test (p=0.001).
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Table 5: Analysis of factors associated with overall survival after hepatocellular carcinoma resection in chronic HBV 
patients
Univariate Multivariate P*
P* Hazard Ratio (95% CI)
Gender, (Male Sex) 0.404
Age, (<45 vs ≥45) 0.341
AFP, ng/mL, (≥200) 0.002* 2.120 (1.143-3.930) 0.017*
Existence of liver cirrhosis 0.531
Tumor size, (≤5cm vs >5cm) 0.139
Tumor number, (single vs multiple) 0.304
Existence of satellite nodule 0.643
Edmonson grade, (>2) 0.003*
Existence of microvascular invasion 0.005*
Existence of macrovascular invasion 0.003* 6.016 (1.293-27.990) 0.022*
LN metastasis 0.003*
Etiology of liver disease (Alcohol) 0.039* 8.945 (2.387-33.525) 0.001*
Expression of PDGFRα (Strong)
Tumor site 0.001* 5.462 (1.799-16.582) 0.003*
Non-tumor site 0.171
AFP, alpha-fetoprotein; LN, lymph node; PDGFRα, platelet-derived growth factor receptor α, CI, confidence interval; 
*P values that are <0.05 are considered to be significant.
Figure 3: Disease free survival after the curative resection of hepatocellular carcinoma (HCC) according to PDGFRα 
expression in tumor sites. PDGFRα positivity on tumor sites was not associated with HCC recurrence and disease free survival after 
curative resection (p=0.165).
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Table 6: Analysis of factors associated with disease-free survival after hepatocellular carcinoma resection in chronic 
HBV patients
Univariate Multivariate P*
P* Hazard Ratio (95% CI)
Gender, (Male Sex) 0.599
Age, (<45 vs ≥45) 0.583
AFP, ng/mL, (≥200) 0.098*
Existence of liver cirrhosis 0.673
Tumor size, (≤5cm vs >5cm) 0.040*
Tumor number, (single vs multiple) 0.011* 3.378 (1.172-9.742) 0.024
Existence of satellite nodule 0.449
Edmonson grade, (>2) 0.002* 2.324 (1.135-4.761) 0.021
Existence of microvascular invasion 0.283
Existence of macrovascular invasion 0.000* 48.382 (6.303-371/364) <0.000
Existence of LN metastasis
Etiology of liver disease (Other than virus or alcohol) 0.546
Expression of PDGFRα (Strong)
Tumor site 0.165
Non-tumor site 0.957
AFP, alpha-fetoprotein; LN, lymph node; PDGFRα, platelet-derived growth factor receptor α, CI, confidence interval; 
*P values that are <0.05 are considered to be significant.
Table 7: Summary of hepatocellular carcinoma patients under fresh liver tissue evaluation
Patient 
No
Etiology of Liver 
Disease
AFP* (ng/dL) Liver 
Cirrhosis†
PDGFRα RNA fold  
change‡
Non-tumor Tumor
1 Others 9.9 YES 5.1836 2.0229
2 HBV 2.2 NO 1.1126 0.2511
3 HBV 4.0 NO 1.2189 2.3278
4 HBV 10.5 YES 8.3916 0.1800
5 HBV 159.4 YES 3.9832 0.6502
6 HBV 4.5 NO 1.3416 0.0338
7 HBV 3.9 NO 0.3515 0.8131
8 HBV 308.0 NO 2.2060 0.001
9 HBV 222336.0 NO 3.1909 2.5517
10 HBV 3.1 YES 1.9305 1.9744
11 Others 2.1 NO 0.0836 2.2214
12 HBV 24 YES 6.0166 0.1916
13 HBV 5.3 NO 1.8615 0.0161
14 HBV 3.3 YES 11.5230 2.1494
15 HBV 29.70 NO 4.8955 24.1081
16 HCV 57.5 YES 11.6434 40.6855
* Preoperative serum AFP.
† Liver cirrhosis is detected by pathologic evaluation.
‡ PDGFRα RNA fold changes in tumor and non-tumor sites are expressed in relative to PDGFRα expression in normal liver 
from specimens from patients with metastatic colon cancer.
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generating HCC, this does not indicate that HSCs are the 
cancer-associated fibroblasts in HCC. It may not be even 
appropriate to conclude that PDGRα expressing HSC are 
the source of PDGFRα in HCC with poor prognosis.
The source of PDGFRα in HCC still carries many 
controversies and disputes. While several studies reported 
that PDGFRα positive cells in tumor sites are malignant 
cells themselves [14, 17, 18], another study argued that 
those were invaded non-parenchymal cells that showed 
PDGFRα positive [15]. In this study, we could not clearly 
differentiate PDGFRα positive non-parenchymal cells 
from hepatocytes since PDGFRα positive specimens 
demonstrated extensive brown staining in the target 
sections. However, when the same staining technique 
was applied, in PDGFRα negative sections, we could 
still identify some brown stained non-parenchymal cells 
with negatively stained parenchymal cells. In addition, 
a previous study demonstrated that overexpression of 
PDGFRα in Hep3B promoted cell proliferation, migration 
and invasion that are hallmarks of cancer cells [18]. 
Further studies on PDGFRα in HCC are expected to settle 
this dispute on the source of PDGFRα in HCC.
Table 8: Correlation between PDGFRα in tumor sites and fibrosis or cancer-associated fibroblasts related genes
Genes Correlation with PDGFRα in Tumor sites P value
Tumor Sites
 Col1α(I) 0.472 0.023
 Lrat 0.494 0.017
 αSMA 0.497 0.016
 LOXL2 0.142 0.517
Non-Tumor Sites
 Col1α(I) 0.233 0.284
 Lrat 0.228 0.295
 αSMA 0.160 0.466
 LOXL2 0.221 0.310
 PDGFRα 0.245 0.260
Col1α(I), collagen α1(I); Lrat, lecithin retinol acyltransferase; αSMA, α smooth muscle actin; LOXL2, lysyl oxidase 
homolog 2.
Figure 4: Expression of PDGFRα and other fibrosis related genes in (A) non-tumor sites, and (B) tumor sites according 
to the existence of liver cirrhosis. Freshly frozen HCC specimens with matching non-tumor sites were used for mRNA quantification. 
Gene expression on normal liver, obtained from non-tumor sites of resected liver due to colon cancer metastasized to the liver, served as 
the control.
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Although non-parenchymal cells in HCC might not 
be the major source of PDGFRα, non-parenchymal cells, 
especially HSCs, still seem to play an important role in 
PDGFRα positive HCC. Our study showed that PDGFRα 
expression in tumor site was associated with increased 
Lrat expression in tumor site. Since Lrat can only be 
expressed in HSCs and not in CAF, it can be speculated 
that PDGFRα expression in HCC might be associated 
with increased recruitment of HSCs in the tumor site. 
Moreover, previous fate tracing study revealed that HSCs 
are the dominant myofibroblasts in toxic, cholestatic and 
fatty liver injury [27], and it can be speculated that rise of 
HCC might have stimulated adjacent HSCs, incorporating 
them within the tumor matrix. However, this tumor 
stimulated HSC activation might not necessarily be related 
with underlying liver fibrosis/cirrhosis.
Although studies suggested that strong expression of 
PDGFRα was associated with decreased survival [14, 17, 
18], the proportion of PDGFRα strong positive patients 
showed some discrepancies. This study and another 
previous study reported that PDGFRα consisted only about 
6-7% [17], when the other studied described that high 
PDGFRα was seen in about 38% of HCC patients [18]. 
Very low proportion of PDGFRα strong positive patients 
would hinder the usefulness of PDGFRα as HCC target. On 
the other hands, it has been investigated that overexpression 
of vascular endothelial growth factor (VEGF) which was 
shown in about 20% of HCC patients tended to result in 
shortened overall survival [17], and inhibition and MET 
in MET-positive HCC which consist about 30-40% of 
HCC patients resulted in decreased tumor burden [28, 29]. 
Further studies that provide more consistent information 
on the proportion of PDGFRα positive HCC would put 
PDGFRα as a target for HCC treatment in the future.
There are several limitations in this study. Firstly, 
for the tissue microarray analysis, the results are limited by 
small number of PDGFRα strong positive HCC specimens. 
As another previous study [17] reported, our study also 
showed that about 70% of HCC had PDGFRα positive. On 
the other hands, very small number of patient had strong 
PDGFRα positivity which predisposed poor prognosis 
after the curative liver resection. This study cannot explain 
the pathophysiological difference in moderately positive 
and strong positive expression of PDGFRα since this 
study is an observational study using human specimens. 
Secondly, estimation from frozen human liver specimens 
may be limited by small sample size. In addition, even 
though we used liver specimens from the resected liver 
due to colon cancer with liver metastasis, these specimens 
may not be truly normal due to the metastasized cancer 
cells. Thirdly, as we have stated earlier, our study could 
not clearly identify the source of PDGFRα in HCC and 
differentiated PDGFRα positive non-parenchymal cells 
from parenchymal cells.
In spite of these limitations, this study also showed 
that PDGFRα expression is a poor prognostic marker for 
HCC after the curative surgical treatment, independent of 
underlying liver cirrhotic condition. Although PDGFRα 
is known to be abundantly expressed in activated 
HSCs, PDGFRα in tumor sites was not associated with 
underlying liver fibrosis/cirrhosis. Instead, PDGFRα 
expression in HCC was accompanied by enhanced Lrat 
expression, suggesting increased HSC residence in tumor 
sites.
MATERIALS AND METHODS
Liver specimens and patient information
This observational, retrospective study used 
paraffin-embedded HCC samples from surgical resection 
and freshly frozen liver tissue archived at the Tissue Bank. 
This study was approved by the institutional review board 
of Inha University Hospital (Incheon, Korea) and Yonsei 
University College of Medicine Gangnam Severance 
Hospital (Seoul, Korea).
The paraffin-embedded 95 HCC samples were 
from the patients who underwent liver resection between 
January 2000 and August 2010 at Inha University 
Hospital. Patients were 29-75 years in age (range, 53.2 
± 10.0, mean ± standard deviation (SD)), consisted of 78 
males and 17 females. Mean follow-up time after surgery 
was 50.0 ± 39.3 months (range, 0-108). These patients 
received no preoperative treatment for HCC and had 
curative liver resection. These 95 patients were regularly 
followed up for HCC recurrence. AFP measurements 
were done every 3 months, and dynamic CT was regularly 
performed with the interval no longer than 6 months. 
All the patients were followed until the time of death or 
for at least 12 months. When a new lesion was detected 
by abdominal CT, evaluation for HCC recurrence was 
performed. When the liver CT showed compatible findings 
with HCC with accompanied AFP elevation, recurrence 
was diagnosed. However, if vascular pattern was not 
typical on liver CT, liver MRI and/or hepatic angiogram 
(HA) was performed. When the nodule showed atypical 
pattern on all the imaging studies, the nodule was followed 
up with the interval no longer than 3 months. In case of 
elevated AFP without evidence of newly appeared lesion 
on CT, magnetic resonance imaging (MRI) and/or HA 
was performed. Histopathologic analysis was performed 
on whole tissue section and the variables recorded for 
each case included tumor size, differentiation according 
to Edmondson-Steiner grade, presence of multiple tumors, 
microvascular and major vessel invasion, and background 
cirrhosis.
The freshly frozen liver tissue was archived at the 
Tissue Bank of Yonsei University College of Medicine, 
Gangnam Severance Hospital after the acquisition of 
patients’ consent. From the bank, 16 HCC specimens with 
matching non-tumor site liver tissue were used for the 
analysis. Non-tumor site of the liver tissue resected from 
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colon cancer patients due to liver metastasis (n=7) served 
as the normal control. Patient with HCC had liver resection 
between January 2012 and December 2014. Patients were 
24-69 years in age (range, 57 ± 10.6), consisted of 9 males 
and 7 females. Mean follow-up time after surgery was 34 
± 21.6 months (range, 2.5-36.7). These patients received 
no preoperative treatment for HCC and had curative liver 
resection.
Tissue microarray construction
Core tissue biopsies were taken from paraffin-
embedded donor blocks and arranged in corresponding 
recipient tissue-array blocks using homemade recipient 
agarose-paraffin blocks as previously described [30]. At 
least 2 cores were sampled from the target lesions. When 
there were multiple nodules, the largest nodule served as 
the target lesion of the tumor site. Target lesions consisted 
of tumor sites and corresponding non-tumor sites for each 
patient.
Immunohistochemistry (IHC) analysis
Immunohistochemical stain using mouse mono-
clonal antibody against PDGFRa (SC-338, Santa Cruz, 
CA, 1:50 dilution) was performed as previously described 
on other studies [31]. The result was interpreted in a semi-
quantitative manner. In cases of positive cells < 5% was 
considered as negative stain, and those > 5% was positive. 
In the positive cases, the scoring was performed according 
to the strength of the immunostaining as weak staining, 
moderate staining, and strong staining.
RNA extraction and gene expression analysis by 
quantitative real-time polymerase chain reaction 
(PCR)
Total RNA was extracted from frozen whole using 
Trizol reagent (Invitrogen, Carlsbad, CA, USA) or Qiagen 
mini columns (Quiagen Inc. Valencia, CA, USA) according 
to the manufacturer’s protocol. RNA samples were 
quantified by spectrophotometry. The RNA integrity was 
assessed using agarose gel electrophoresis and ethidium 
bromide staining. The RNA samples were then diluted 
in RNase-free water and stored at −70 °C until use. Five 
micrograms of RNA were reverse-transcribed using RNA 
PCR kit version 1.2 (Takara Bio Inc, Japan) according to the 
manufacturer’s recommendations. Oligonucleotide primers 
and TagMan probe for PDGFRα, Col1α(I), Lrat, αSMA, 
and LOXL2 were used with 18S as an internal control. The 
probes were obtained from Applied Biosystems (Perkin-
Elmer/PE Applied Biosystems, Forster City, CA, USA), 
purchased as a ready-for-use form in Assays-on-Demand 
Gene Expression Products. The TaqMan probes was labeled 
at the 5’ end with the reporter dye FAM and minor groove 
binder (MGB) nonfluorescent quencher on the 3’end. The 
quantitative PCR was performed in triplicate for each 
sample on Step One Plus Real Time System (Applied 
Biosystems). Each 20-μL reaction contained 10 uL of 
TaqMan Fast Universal Master Mix (Applied Biosystems, 
Darmstadt, Germany), 1 uL of Gene Expression Mix and 2 
uL of cDNA diluted in 7 μL RNase-free water. The thermal 
cycler conditions were 20 seconds at 95˚C, and 40 cycles 
of 5 seconds at 95˚C followed by 20 seconds at 60˚. Fold 
change of mRNA in target genes relative to the endogenous 
18S control were calculated as suggested on previous 
studies [32].
Statistical analysis
Categorical variables were compared using two-
sided χ2-test or Fisher’s exact test when appropriate, 
and continuous variables were compared using the 
independent sample t-test or Kruskall-Wallis test. Factors 
predicting HCC recurrence and survival were analyzed 
using Cox proportional hazard model. Variables with 
p<0.05 from two-tailed test in univariable analysis were 
included in the multivariable model. These models were 
considered using conditional selection procedures. Hazard 
ratios (HRs) were presented with 95 percent confidence 
interval. P<0.05 from two-tailed test was considered 
significant for multivariate analysis. Statistical analyses 
were performed using SPSS software version 15.0 (SPSS, 
Chicago, IL).
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